# Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis

> **NCT06590545** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **David Simon** · enrollment: 8 (estimated)

## Conditions studied

- ANCA-IgG-positive ANCA Associated Vasculitis

## Interventions

- **DRUG:** KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

## Key facts

- **NCT ID:** NCT06590545
- **Lead sponsor:** David Simon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-07
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590545, "Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06590545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*